Register to view the archived recording here.
In the Latest Big Pharma/RNAi Alliance, Alcon Inks Deal with Dharmacon for Eye Diseases
For Dharmacon, it represents the first step towards moving beyond its role as simply an RNAi oligo and tool provider in a market that has become increasingly saturated with competition. Subscribers: click headline for more
New to GenomeWeb? Register here quickly.